A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival by Keane, Colm et al.
Oncotarget23620www.oncotarget.com
A high LDH to absolute lymphocyte count ratio in patients with 
DLBCL predicts for a poor intratumoral immune response and 
inferior survival
Colm Keane1,2, Joshua Tobin1,2, Dipti Talaulikar3,4, Michael Green5, Pauline Crooks6, 
Sanjiv Jain3,4 and Maher Gandhi1,2
1University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, 
Queensland, Australia
2Princess Alexandra Hospital, Brisbane, Queensland, Australia
3Canberra Hospital, Canberra, Australian Capital Territory, Australia
4Australian National University Medical School, Canberra, Australian Capital Territory, Australia
5MD Anderson Cancer Centre, Houston, Texas, USA
6Queensland Institute of Medical Research, Brisbane, Queensland, Australia
Correspondence to: Colm Keane, email: c.keane@uq.edu.au
Keywords: DLBCL; tumor microenvironment
Received: January 15, 2018    Accepted: April 06, 2018    Published: May 04, 2018
Copyright: Keane et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Purpose: To test the utility of the circulating Lactate Dehydrogenase (LDH) to 
absolute lymphocyte count (ALC) ratio (LAR) to predict outcome to conventional 
first-line chemo-immunotherapy in Diffuse Large B-cell Lymphoma (DLBCL), and 
investigate its correlation to the tumour immune microenvironment (TME).
Experimental Design: A population based cohort of 210 patients (median age: 
64, range 18-90 years) with median follow up 3.8 years was analysed. All patients 
were treated with R-CHOP, and no immunosuppression related cases were included. 
Tissue for nanoString gene expression was available in 141.
Results: High (i.e. adverse) LAR was associated with inferior progression free 
and overall survival (PFS 45% vs. 78%; OS 56% vs 86%, both p<0.001) at 5-years. 
Patients with a high LAR had a strikingly different TME compared to patients with 
a low ratio. Low LAR was associated with a good-risk TME immune gene signature 
(p<0.0001), including high CD8 and lower M2 macrophage infiltration. COO 
classification was not significantly different between high and low LAR patients. 
LAR was predictive of outcome independent of cell of origin and the international 
prognostic index (IPI). In particular, LAR discriminated patients with high IPI (3-
5), showing 5-year PFS and OS of 32% vs. 74% (p=0.0006), and 43% vs. 81% 
(p=0.0003). A combined nanoString based immune score and the LAR allowed better 
prediction of outcome than either prognosticator alone (p<0.0001).
Conclusions: The LAR reflects the TME within DLBCL, and is a strong predictor 
of outcome in DLBCL treated with conventional first-line therapy that is independent 
of and additive to the IPI. Further studies are required to determine if this easily 
applicable blood assay can determine patients that might benefit from immune 
checkpoint blockade.
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INTRODUCTION
Diffuse Large B-cell Lymphoma (DLBCL) is the 
most common aggressive lymphoma. Incorporation 
of rituximab to front-line chemotherapy has improved 
outcomes, but approximately one third of patients will 
relapse with subsequent poor prognosis [1–4]. The chance 
of cure with relapsed or refractory disease is very poor 
and a current clinical unmet need is for biomarkers that 
enables patients to be stratified for targeting with alternate 
agents. In particular, immune based therapies are likely to 
be most effective at an earlier time-point in the course of a 
patient’s treatment [5, 6].
The International Prognostic Index (IPI) is a 
robust prognostic score developed over 20 years ago 
that is still predictive of outcome in the era of chemo-
immunotherapy (e.g. ‘R-CHOP’) [7]. Some modifications 
to prognostic groupings have been required with the 
influence of the addition of rituximab to therapy but the 
IPI maintains its prognostic significance [8]. This score 
encompasses 4 clinical factors and lactose dehydrogenase 
as the one circulating factor. Despite its usefulness for 
prognostication, it does not guide therapy nor result in 
different strategies based on a low or high score in routine 
clinical practice. Patients with the poorest prognostic 
score still have an overall survival of greater than 50%. 
Better identification of patients destined to have relapsed 
or refractory disease would guide therapy in an era where 
newer agents such as targeted immunotherapies are 
emerging.
We have previously shown that an immune score 
that measures immune effectors and immune checkpoints 
quantified by nanoString digital multiplex gene expression 
in DLBCL is highly predictive and is both independent 
and additive to the IPI and cell of origin (COO) [9]. 
Immune checkpoint therapy and in particular anti-PD1 
has demonstrated surprisingly robust responses in relapsed 
refractory Hodgkin Lymphoma [10]. Excellent responses 
have also been demonstrated in relapsed/refractory 
DLBCL [11]. It has been postulated that immune 
checkpoint therapy may be highly effective in certain 
DLBCL subtypes such as Epstein-Barr virus (EBV)-
positive DLBCL and primary central nervous system 
lymphoma [12, 13]. It is however unclear in systemic 
de-novo DLBCL which patients may benefit from novel 
therapeutic approaches including checkpoint blockade. A 
circulating surrogate of the TME would provide important 
prognostic information and assist identification of patients 
that may benefit from risk-stratification to new therapies.
Poor prognosis is associated with a low absolute 
lymphocyte count and also the lymphocyte to monocyte 
ratio (LMR) in predicting outcome for patients with 
DLBCL treated with R-CHOP [14, 15]. Not only is a 
low lymphocyte count prognostic at diagnosis but also 
lymphopenia during routine follow-up after chemo- 
immunotherapy is a risk factor for predicting relapse [16, 
17]. However, to date no simple circulating biomarker 
has shown useful correlations with the intratumoural 
environment present within the diagnostic biopsy. 
However, recent studies have shown that in lymphoma, 
LDH correlates strongly with higher levels of cell free 
tumour DNA and might be a surrogate of increased 
circulating tumour cells [18, 19]. In solid tumours such 
as metastatic melanoma disease bulk is directly related to 
LDH level [20]. In addition, there is emerging evidence 
that high levels of lactate in the tumour microenvironment 
(TME) results in significant inhibition of T cell function 
and is a possible mechanism of resistance to immune 
checkpoint therapy [21].
In metastatic melanoma treated with immune 
checkpoint blockade, elevated levels of LDH and low 
ALC counts are associated with significantly inferior 
responses [22]. If results are replicated in patients with 
DLBCL treated with conventional first-line R-CHOP 
chemo-immunotherapy, this will have the potential to 
assist selection of patients with DLBCL destined to 
be refractory to R-CHOP that might be candidates for 
checkpoint blockade within clinical trials [11]. Therefore, 
the aim of the current study was to investigate if the 
ratio of LDH to absolute lymphocyte count (LAR) at 
diagnosis is prognostic in patients with DLBCL treated 
with R-CHOP. The relationship between these circulating 
biomarkers and the intratumoural microenvironment was 
also investigated.
RESULTS
Patients’ characteristics
The median age of all patients (n=210) was 64.5 
years (range 18-89), and the median follow-up was 3.8 
years for all patients. The estimated 5-year PFS and 
OS was 67% and 76% respectively. The IPI score was 
available in 206 and was prognostic with 5-year survival 
for low IPI (0-2) of 87% compared to 57% for high IPI 
patients (IPI 3-5) (p<0.0001). COO by nanoString was 
available in 141 patients (66% Germinal Centre B cell 
DLBCL; 21% Activated B cell DLBCL; 13% unclassified) 
and was prognostic with 5-year survival for GCB-DLBCL 
of 87% compared to 53% for ABC-DLBCL patients 
(p=0.001).
A high LAR score is associated with adverse 
prognosis
The median ALC was 1.2 x 109/L (interquartile 
range [IQR] 0.76-1.89 x 109/L, range 0.12-5.31 x 109/L) 
and the median LDH count was 296 U/L (IQR 224-515 
U/L, range 87-12233 U/L). A cut-off of 400 was the most 
discriminatory LAR value for overall survival. Using 
this cut-off value a high LDH to ALC ratio (LAR) score 
was associated with a significantly inferior PFS and OS 
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compared to patients with a low score with 5-year PFS 
(45% vs 78%, HR 4.2 (95% CI 2.3-7.44, p<0.001) and 
OS (56% vs. 86%, HR 4.4 (95% CI 2.33-8.44, p<0.001) 
(see Figure 1). Of note, the LAR score was predictive 
of overall survival as a continuous variable (p=0.037) 
(Supplementary Figure 1). A high LAR score was 
strongly associated with 4 of the 5 components of the 
IPI (Table 1): not only were patients with a high LAR 
score (as expected) enriched for high LDH (p<0.0001), 
but also for higher clinical stage (p=0.0002), ECOG>1 
(p=0.003), extranodal sites>1 (p=0.034). However, age 
>60 was not associated (p=0.65). A high LAR score was 
also associated with an EBV positive biopsy at diagnosis 
(p=0.015). For each of the individual components of 
the IPI (except Stage > II trend only), the LAR score 
was able to further stratify OS into two survival groups 
(Supplementary Figure 2). Of note, LAR discriminated 
patients with high IPI (3-5) in particular, showing 5-year 
PFS and OS for high and low LAR respectively of 32% 
vs. 74% (p=0.0006) HR 3.48(95% CI 1.75-6.75), and 
43% vs. 81% (p=0.0003) HR 4.47(95% CI 2.2-9.03). 
There were no significant differences in the distribution 
of COO between the two LAR groups (p=0.09). The LAR 
score was however a significant predictor of outcome in 
the GCB subtype (92/141) but not the ABC/Unclassified 
groupings (49/141). Patients who had a low LAR score 
and were classified GCB had a 5-year OS of 98% vs. 
64% HR 25.7(95% CI 7.5-88.34) with a high LAR score 
(p<0.0001).
LAR is reflective of the TME
There were 141 patient samples with a LAR score 
that had sufficient tissue for digital gene expression to 
be performed (see Supplementary Dataset 1). The M2 
count was calculated as a ratio of the CD163 to CD68 
digital counts obtained. A high (adverse) LAR score was 
associated with significantly higher M2 macrophage 
count (p=0.0012) but a markedly decreased intra-tumoral 
CD8 count (p=0.044) (Figure 2A, 2B). This is despite 
the ALC on its own not predicting for the level of CD8 
T cell infiltration in the TME (p=0.4). There was no 
difference between LAR high and low groups with regard 
to CD4 counts. The LAR score had a low to modest but 
significant positive correlation with the M2 ratio (r=0.24, 
p=0.003) but there was no correlation between the LAR 
score and CD4 or CD8 infiltration. We have previously 
identified a gene expression immune score derived from 
tumour biopsies that was highly prognostic in patients 
with DLBCL treated with R-CHOP, independent of IPI 
and gene expression based COO [9]. A good risk immune 
score indicates a high level of immune effectors relative 
to immune checkpoints, thus low scores are predictive 
of adverse outcome. In the current study, patients with 
a high LAR score had a median immune score that 
was 4 times lower than patients with a low LAR score 
(p<0.0001, Figure 2C). Patients with a good prognostic 
immune score were significantly more likely to have a 
low LAR score (p=0.0007). The LAR score showed a 
low to modest negative correlation with the immune score 
(r= -0.3, p=0.0003). These results indicate that the LAR 
is a circulating biomarker that partially reflects the TME 
within the diagnostic tumour biopsy.
A combined immune and LAR score is highly 
prognostic
Not only was the immune score highly prognostic 
but importantly a combined immune and LAR score added 
to the prognostic utility of either prognosticator alone, 
allowing prognosis to be split into three highly disparate 
survival groups (Figure 3). Patients with a good risk 
immune score had 5-year outcome of 97%. There were 
61% patients in this category. Poor risk immune score 
Figure 1: Survival stratified by the LAR score. Kaplan-Meier survival curves for 210 patients stratified by the LAR score. (A) 
Progression free and (B) overall survival.
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patients with a low LAR score had 5-year OS of 54% 
(21% of patients), and those with both a poor risk immune 
score and a high LAR score had 5-year OS of 32% (18% 
of patients). This illustrates that a circulating measure of 
immune response provides additional information to intra-
tumoral assessment of immune responses garnered from 
gene expression data. It also indicates that poor immune 
response in both the TME and the circulation is associated 
with very poor outcome. Interestingly, the only two deaths 
seen in patients with a good prognosis immune score 
were in patients with a high LAR score but this was not 
statistically significant (p=0.08).
Multivariate survival analysis
The LAR score was included in a multivariate 
analysis of OS with the IPI score (there were 206 patients 
in whom a full multivariate analysis was possible). This 
showed that the LAR score was independently prognostic 
for PFS (P=0.001) and OS (p=0.002). In the 141 patients 
with nanoString based immune score and COO available, 
a further multivariate analysis was performed including 
the IPI along with the LAR score. Both the LAR score and 
immune Score maintained their significance independent 
of IPI and COO for PFS (p=0.043 and p<0.001) and OS 
(p=0.026 and p<0.001).
DISCUSSION
The IPI has remained at the cornerstone of 
prognostication in DLBCL over the last 20 years. Despite 
its usefulness, it still currently provides no guidance on 
therapy selection. Attempts have been made to develop 
gene expression or IHC algorithms but to date a lack of 
standardisation and availability of technology have made 
it difficult for any biomarker derived from these methods 
to be used in widespread clinical practice. The present 
study demonstrates that an easily accessible and simple 
to use assay - the LAR - reflects the TME in DLBCL, 
and is a strong predictor of outcome in DLBCL treated 
with conventional first-line chemo-immunotherapy that is 
independent of and additive to the IPI.
The prognostic importance of LDH levels and 
ALC in predicting outcome to immune based therapies 
in solid tumours has recently been described [22]. These 
findings appear consistent across the subtype of immune 
checkpoint blockade therapies utilised to date [23]. High 
LDH has long been associated with poor outcome in 
DLBCL while the ALC has more recently been shown by 
us and others to be prognostic in patients with DLBCL 
treated with R-CHOP. It is postulated that while elevated 
LDH may reflect high cell turnover of aggressive disease, 
it has also been demonstrated that high lactate levels 
within the tumour bed can “stun” T cell responses [24].
We demonstrate for the first time that a high ratio 
of LDH to ALC was highly predictive of outcome in the 
setting of patients with DLBCL treated with R-CHOP. This 
was independent of previously described prognosticators 
including the IPI and COO. Strikingly, the LAR was 
reflective of an immune score that is generated from gene 
expression of the TME within the diagnostic biopsy. This 
immune score was on average 4-fold higher in the good 
prognosis low LAR patients. This data suggests a strong 
link between LDH and immune response to tumours. 
Despite this association, the LAR was still prognostically 
independent of this immune signature underscoring the 
complexity and differences of immune response between 
the circulation and the TME. Interestingly in the patients 
in whom COO was performed, the LAR score seemed to 
predict outcome most strongly in the GCB group. Patients 
who were classified GCB but had a high LAR score had 
a surprisingly poor outcome. We feel that the LAR score 
may identify the ability of the patient’s immune system 
to clear their lymphoma. A high LAR score may reflect 
that a patient with a low lymphocyte count and a high 
tumour tumor burden is unable to mount effective long 
Table 1: Association between LAR and the IPI
Patient Characteristics LAR High (n=68) LAR Low (n=142) P value
Age>60 45 (66%) 88 (62%) 0.65
Stage>II 50 (75%) 64 (46%) 0.0002
ECOG>1 29 (43%) 26 (19%) 0.0003
EN>1 28 (42%) 35 (25%) 0.0345
LDH>N 58 (87%) 58 (41%) <0.0001
IPI
0 1 (1%) 20 (14%) <0.0001
1,2 20 (30%) 77 (56%)
3,4,5 46 (69%) 42 (30%)
Full data on all the IPI individual components was available in 206 of 210 patients.
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term immunologic control of their lymphoma despite 
chemotherapy. We anticipate that a combination of the 
LAR score with other immunologic, molecular and genetic 
prognosticators will allow new insights into the prediction 
of responses to emerging agents such as immune 
checkpoint blockade and CAR-T cell therapy.
LDH itself appears critical for tumour progression 
in many cancers. Tumour cells favour glycolysis over 
oxidative phosphorylation even in the presence of oxygen. 
This phenomenon, called the Warburg effect, appears 
critical to tumour development [25]. LDH is a critical 
enzyme in this process and catalyses the generation of 
lactate from pyruvate. Additionally, the large glucose 
utilization by tumours and the production of lactate 
has a significant role in reducing the effectiveness of 
immune effectors within the tumour microenvironment 
with consequent skewing of the TME towards one of 
immune suppression [21, 26]. Our data is consistent 
with this, with a reduced ALC being associated with 
higher levels of LDH. In addition, the poor prognosis 
high LAR ratio is strongly associated with an increase 
in M2 macrophages. A TME high in lactate has recently 
been associated with skewing of tumour associated 
macrophages to an immunosuppressive M2 phenotype 
[21]. Tumour infiltrating lymphocytes have to compete 
with tumour cells for glucose and high levels of lactate 
in the TME appear to reduce effective T cell function. It 
has also been postulated that high lactate levels create 
a more tolerogenic environment for other immune cells 
including dendritic cells, monocytes and NK cells [24, 
25]. Indeed, evidence points to the direct targeting of LDH 
as a potential therapeutic avenue in cancer [26].
A number of recent studies indicate that LDH 
is also an effective marker of tumour bulk in solid and 
haematological malignancies [19, 20]. Of particular 
interest is a recent study describing predictors of response 
in patients treated with pembroluzumab in the setting 
of metastatic melanoma. This study demonstrated that 
many patients appear to demonstrate reinvigoration of 
the immune system with therapy but that only 50% of 
Figure 2: Association between LAR score and the intratumoural immune microenvironment. (A) CD8 mRNA expression 
(B) M2 Macrophage load (derived from mRNA expression ratio of CD163/CD68) (C) immune score.
Figure 3: Impact of a combined immune score/LAR reflecting one group of “good immune score” alone, and the “poor prognosis” 
immune score patients stratified by a high or low LAR score with regard to (A) progression free and (B) overall survival.
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patients actually demonstrate clinical response despite 
immune activation [20]. It was demonstrated that this 
may be due to tumour bulk (in which LDH was found to 
strongly correlate in this study) which may elicit a large 
but ultimately futile immune response.
In summary, the LAR score is calculated from 
simple blood assays widely available to all physicians 
treating this disease. It is partially reflective of the TME, 
but as an independent variable also adds additional 
information. The prognostic importance of the LAR after 
conventional front-line therapy will need to be confirmed 
in other cohorts and in prospective studies. Patients with 
high LAR scores might benefit from new immune based 
therapies, and as with malignant melanoma, studies 
are required to test if LAR is a predictive biomarker of 
response to immune checkpoint blockade. Research into 
the effects of LDH and lactate on both tumour growth and 
immune evasion is warranted to investigate the biological 
basis for our findings.
MATERIALS AND METHODS
Patients
The study was approved by Ethics Committees at 
participating sites. Patients with DLBCL and treated with 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisolone) between 2004 and 2013 
were included. There were 210 patients from two 
participating centres. There were 120 patients from the 
Princess Alexandra Hospital (Queensland, Australia) and 
90 patients from Canberra Hospital (Australian Capital 
Territory, Australia). All patients received R-CHOP, and 
were otherwise selected solely on the availability of 
clinical annotation (including survival data) and results for 
LDH and absolute lymphocyte count prior to initiation of 
therapy. The LAR score is a simple ratio of the measured 
LDH level over the ALC, e.g. a LDH value of 1000 U/L 
in a patient with an ALC of 0.5 x 109/L would give a LAR 
ratio score of 2000 whereas a LDH level of 250 U/L with 
an ALC of 2.5 x 109/L would give a LAR score of 100. 
Only de novo cases of DLBCL were included. Grade IIIB 
or transformed follicular lymphoma, HIV-positive and 
post-transplant patients were excluded.
Nanostring™ nCounter RNA quantification
RNA was extracted from available formalin 
fixed paraffin embedded (FFPE) tumour biopsies using 
RecoverAll total nucleic acid extraction kit for FFPE 
(Ambion, Life Technologies, Carlsbad, CA, USA) 
as per manufacturer’s instructions. The previously 
described immune score incorporates the gene counts 
of CD4*CD8/M2*PDL1, with M2 calculated by CD163/
CD68(9). Genes were quantified using the nCounter 
platform (Nanostring™ Technologies, Seattle, WA, 
USA) and the COO was calculated as previously 
outlined [9].
Statistical analysis
Values between groups of data were tested for 
statistical significance using the 2-tailed non-paired 
Mann-Whitney test. Categorical data were compared 
using Fisher’s exact test or Chi-squared test as appropriate. 
Progression-free survival (PFS) was determined from the 
date of diagnosis to the date of last follow-up or disease 
progression, death, or discontinuation of treatment for any 
reason. Overall survival (OS) was determined from the 
date of diagnosis to the date of last follow-up or death. 
Survival analysis was performed using Kaplan–Meier 
curves and the log-rank test. Tests were two sided at 
p=0.05. Multivariate analysis was performed using Cox 
regression. Analyses were prepared using GraphPad Prism 
(version 6, La Jolla California USA), Statistical Package 
for the Social Sciences version 24 (International Business 
Machines Corporation, New York USA).
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